Corbus Pharmaceuticals Holdings, Inc.

By 2040, over half a billion people could be taking GLP-1 agonists or other weight loss medicines, according to McKinsey. A market that barely existed prior to 2021 could be worth over $100bn by 2030

The Jefferies London Healthcare Conference is now in its 15th year, and is firmly established as Europe’s biggest biopharma investment meeting. Here are some key themes to watch out for at the event,

Promising early results from novel cancer immunotherapies have been behind the some of the most meteoric share price increases of 2024 so far. An analysis of stock movements from Evaluate Pharma’s dat

Corbus Pharmaceuticals is continuing a share price growth streak as investors warm to its plans for an antibody drug conjugate (ADC) to compete with Pfizer and an obesity drug to rival Novo Nordis